Abstract
This goal of this study is to assess the safety and immunogenicity of recombinant zoster
virus in young adult solid organ transplant recipients. In this study, participants will
receive the recombinant zoster vaccine. They will be monitored for adverse events and tested
for antibody and cellular immunity.
